Skip to content

Study · In vitro (cells) · mouse · 2000

5 results

Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level.

Giuliani C, Napolitano G, Mastino A, Di Vincenzo S, D'Agostini C, Grelli S, Bucci I, Singer DS, Kohn LD, Monaco F, Garaci E, Favalli C

European journal of immunology1 Mar 2000Cited by 77 (Europe PMC)

PMID10741392 (opens in a new tab)DOI10.1002/1521-4141(200003)30:3<778::aid-immu778>3.0.co;2-i (opens in a new tab)PepBankPUB-10741392
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In FRTL-5 cells, thymosin-alpha1 increased surface expression of MHC class I molecules; expression of surface molecules and mRNA together peaked at 153 +/- 8 % of the control value after 12 h.

    In plain wordsIn cells, thymosin alpha‑1 raised the amount of MHC class I molecules on the cell surface.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMHC class I surface expression
    Study

    n: not reported in source

    FRTL-5 cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Peak MHC class I expression
    153 % of control
    12 h

    Source sentences

    Summary
    Treatment with T(alpha)1 increased expression of MHC class I surface molecules and mRNA, which reached its peak (153 +/- 8 % of the control value) after 12 h.
    1 context sentence
    Summary · context
    In this study we examined the effect of the synthetic peptide thymosin-alpha1 (T(alpha)1) on MHC class I expression in FRTL-5 cells.
  2. 02LabIn vitro (cells)Activity measurement

    In FRTL-5 cells, thymosin-alpha1 increased MHC class I mRNA; expression of surface molecules and mRNA together peaked at 153 +/- 8 % of the control value after 12 h.

    In plain wordsIn cells, thymosin alpha‑1 raised the amount of MHC class I messenger RNA.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMHC class I mRNA expression
    Study

    n: not reported in source

    FRTL-5 cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Peak MHC class I expression
    153 % of control
    12 h

    Source sentences

    Summary
    Treatment with T(alpha)1 increased expression of MHC class I surface molecules and mRNA, which reached its peak (153 +/- 8 % of the control value) after 12 h.
    1 context sentence
    Summary · context
    In this study we examined the effect of the synthetic peptide thymosin-alpha1 (T(alpha)1) on MHC class I expression in FRTL-5 cells.
  3. 03LabIn vitro (cells)Mechanism

    In FRTL-5 cells, CAT reporter and mobility shift assays showed thymosin-alpha1 acts at the transcriptional level, probably through increased binding of the p50/fra-2 complex to the enhancer A sequence.

    In plain wordsIn cells, thymosin alpha‑1 appears to act on gene transcription, likely by increasing binding of a protein complex to a DNA enhancer.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTranscriptional regulation of MHC class I
    Study

    n: not reported in source

    FRTL-5 cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    demonstrated that the action of T(alpha)1 was at the transcriptional level, and its mechanism of action is likely due to increased binding between the complex p50/fra-2 and the enhancer A sequence
    1 context sentence
    Summary · context
    In this study we examined the effect of the synthetic peptide thymosin-alpha1 (T(alpha)1) on MHC class I expression in FRTL-5 cells.
  4. 04LabIn vitro (cells)Activity measurement

    In murine and human tumor cell lines, thymosin-alpha1 increased surface expression of MHC class I molecules by flow cytometry.

    In plain wordsIn mouse and human tumor cell lines, thymosin alpha‑1 raised MHC class I molecules on the cell surface.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMHC class I surface expression in tumor cell lines
    Study

    mouse and humann: not reported in source

    murine and human tumor cell lines
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    An increase in the expression of MHC class I surface molecules was also observed by flow cytometry in murine and human tumor cell lines and in primary cultures of human macrophages.
  5. 05LabIn vitro (cells)Activity measurement

    In primary cultures of human macrophages, thymosin-alpha1 increased surface expression of MHC class I molecules by flow cytometry.

    In plain wordsIn human macrophages grown in the lab, thymosin alpha‑1 raised MHC class I molecules on the cell surface.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMHC class I surface expression in primary macrophages
    Study

    humann: not reported in source

    primary cultures of human macrophages
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    An increase in the expression of MHC class I surface molecules was also observed by flow cytometry in murine and human tumor cell lines and in primary cultures of human macrophages.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT07644897

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

Sun Yat-sen Universityn = 5530 May 2023 to est. 30 Sept 2027

Melanoma · Immune-related Adverse Event · Immune Checkpoint Inhibitor

Trial pageClinicalTrials.govUpdated 12 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.